Posterior reversible encephalopathy syndrome (PRES) and myeloma
Posterior reversible encephalopathy syndrome (PRES) has rarely been described in myeloma, but chemotherapy is a known risk factor. We report 3 patients with myeloma who developed PRES, and analyzed them with 13 published cases, mostly women. The most frequent causative agents were proteasome inhibit...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Leukemia Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S221304892300047X |
| _version_ | 1797370943345000448 |
|---|---|
| author | Ricardos Ghanem Sylvie Glaisner Arthur Bobin Anne-Marie Ronchetti Sophie Cereja Bertrand Joly Célia Salanoubat Guillemette Fouquet |
| author_facet | Ricardos Ghanem Sylvie Glaisner Arthur Bobin Anne-Marie Ronchetti Sophie Cereja Bertrand Joly Célia Salanoubat Guillemette Fouquet |
| author_sort | Ricardos Ghanem |
| collection | DOAJ |
| description | Posterior reversible encephalopathy syndrome (PRES) has rarely been described in myeloma, but chemotherapy is a known risk factor. We report 3 patients with myeloma who developed PRES, and analyzed them with 13 published cases, mostly women. The most frequent causative agents were proteasome inhibitors and autologous stem cell transplantation. Risk factors were frequently associated: hypertension, infection or renal failure. Symptoms included headache, blurred vision, altered mental status, seizures. Most patients experienced rapid clinical recovery, without relapse even after resuming treatment. Although rare, we must remain vigilant about PRES in myeloma patients. Stricter control of blood pressure could limit its occurrence. |
| first_indexed | 2024-03-08T18:11:30Z |
| format | Article |
| id | doaj.art-6d69896bf43f426d9f569022bcaffa54 |
| institution | Directory Open Access Journal |
| issn | 2213-0489 |
| language | English |
| last_indexed | 2024-03-08T18:11:30Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Leukemia Research Reports |
| spelling | doaj.art-6d69896bf43f426d9f569022bcaffa542024-01-01T04:06:01ZengElsevierLeukemia Research Reports2213-04892024-01-0121100407Posterior reversible encephalopathy syndrome (PRES) and myelomaRicardos Ghanem0Sylvie Glaisner1Arthur Bobin2Anne-Marie Ronchetti3Sophie Cereja4Bertrand Joly5Célia Salanoubat6Guillemette Fouquet7Centre Hospitalier Sud Francilien, Hématologie clinique, Corbeil-Essonnes, FranceDépartement d'oncologie médicale, Institut Curie, Paris, FranceService d'Hématologie et Thérapie Cellulaire, Pôle Régional de Cancérologie, CHU de Poitiers, FranceCentre Hospitalier Sud Francilien, Hématologie clinique, Corbeil-Essonnes, FranceCentre Hospitalier Sud Francilien, Hématologie clinique, Corbeil-Essonnes, FranceCentre Hospitalier Sud Francilien, Hématologie clinique, Corbeil-Essonnes, FranceCentre Hospitalier Sud Francilien, Hématologie clinique, Corbeil-Essonnes, FranceCentre Hospitalier Sud Francilien, Hématologie clinique, Corbeil-Essonnes, France; Université de Paris, INSERM U1016, Institut Cochin, CNRS UMR8104, Faculté de médecine Cochin-Port Royal, Paris, France; Corresponding author.Posterior reversible encephalopathy syndrome (PRES) has rarely been described in myeloma, but chemotherapy is a known risk factor. We report 3 patients with myeloma who developed PRES, and analyzed them with 13 published cases, mostly women. The most frequent causative agents were proteasome inhibitors and autologous stem cell transplantation. Risk factors were frequently associated: hypertension, infection or renal failure. Symptoms included headache, blurred vision, altered mental status, seizures. Most patients experienced rapid clinical recovery, without relapse even after resuming treatment. Although rare, we must remain vigilant about PRES in myeloma patients. Stricter control of blood pressure could limit its occurrence.http://www.sciencedirect.com/science/article/pii/S221304892300047XMyelomaNeurotoxicityCerebrovascular complicationPosterior reversible encephalopathy syndromeChemotherapy |
| spellingShingle | Ricardos Ghanem Sylvie Glaisner Arthur Bobin Anne-Marie Ronchetti Sophie Cereja Bertrand Joly Célia Salanoubat Guillemette Fouquet Posterior reversible encephalopathy syndrome (PRES) and myeloma Leukemia Research Reports Myeloma Neurotoxicity Cerebrovascular complication Posterior reversible encephalopathy syndrome Chemotherapy |
| title | Posterior reversible encephalopathy syndrome (PRES) and myeloma |
| title_full | Posterior reversible encephalopathy syndrome (PRES) and myeloma |
| title_fullStr | Posterior reversible encephalopathy syndrome (PRES) and myeloma |
| title_full_unstemmed | Posterior reversible encephalopathy syndrome (PRES) and myeloma |
| title_short | Posterior reversible encephalopathy syndrome (PRES) and myeloma |
| title_sort | posterior reversible encephalopathy syndrome pres and myeloma |
| topic | Myeloma Neurotoxicity Cerebrovascular complication Posterior reversible encephalopathy syndrome Chemotherapy |
| url | http://www.sciencedirect.com/science/article/pii/S221304892300047X |
| work_keys_str_mv | AT ricardosghanem posteriorreversibleencephalopathysyndromepresandmyeloma AT sylvieglaisner posteriorreversibleencephalopathysyndromepresandmyeloma AT arthurbobin posteriorreversibleencephalopathysyndromepresandmyeloma AT annemarieronchetti posteriorreversibleencephalopathysyndromepresandmyeloma AT sophiecereja posteriorreversibleencephalopathysyndromepresandmyeloma AT bertrandjoly posteriorreversibleencephalopathysyndromepresandmyeloma AT celiasalanoubat posteriorreversibleencephalopathysyndromepresandmyeloma AT guillemettefouquet posteriorreversibleencephalopathysyndromepresandmyeloma |